Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Boyds is involved in supporting this www.boydconsultants.com
Nice video by Helen McShane explaining the Oxford news and also goes onto say about discussions with Imperial about the need to manufacture new viral variants to test in HC trials.We know from the November RNS that Orph will play a key global role in the manufacture of these CHIMs in concert with the Wellcome Trust
https://t.co/qZptwgoP13
LOL!
Warren, the tortoise won. :)
Slow and steady....
I think that was £10m to create a covid challenge study and took i think 6mnths(?) to create it and then to get it approved. Other attempts might not even be succesful. I don't foresee us having competition any time soon, especially with our established contacts and relationships with big pharma, there is risk of them spending millions and getting no business at all from it - the risk/reward just wouldn't make sense.
If any competition did appear it would be like the Tortoise and the Hare, and ORPH would not be the Tortoise.
GLA.
Hey Padrock
Personally, I don't see competition anytime soon. To the best of my knowledge ORPH have the only Covid Challenge agent.
And his isn't a vaccine trial - it is a scientific study about re-infection. I'm seeing this as an additional revenue stream for Open Orphan - with virtually no overhead :-)
Big message orignal post?
What competition?
They're using Hvivo's Covid Challenge study model.
Big Pharma could probably do this internally but it's probably cheaper to outsource.
India (the largest producer of vaccines in the world) have opted out of CS's because the cost of setting up a program would be prohibitive.
FYI..SGS do Challenge Studies but have opted out of the Covid CS.
I read it as collaboration not competition. It says they are working with hVIVO.
Did everyone miss the big message in the original post?
We basically have a lot more competition in the covid-19 challenge study space, soon enough people can shop around.
At least we are further ahead of the competition for now.
"With so much potential it is brilliant to see the UK being a leader in utilising human infection studies to help end the pandemic. "
True, and just one aspect of their leadership, but somewhat disappointing that Vaccitech seem to have chosen to IPO on Nasdaq instead of London. They are behind the AZ vaccine and UK Treasury apparently has a stake in them.
They appear to work with wearbles technology amongst many other things
Depends if the 4.8m is the total cost - or just what the Welcome Trust are contributing. A company called Boyd are involved too (is this them : https://www.boydcorp.com/ ??? ) and Oxford University are not short of cash either...
The total cost could be more...
And I think we do need an RNS on this to clarify ORPH's involvement...
We only get a share of the4.8
Still significant that we are mixing it up with the big guys
Looks like the start of new Covid contracts, should be RNS'd?
https://twitter.com/Eskers1/status/1384081362907406345
This month has been historic for vaccines in many ways, one of which has been the commencement of the first human infection study for Covid-19, at Imperial College London in partnership with the UK Government Vaccine Task Force. Today, we hear the exciting news that Oxford University is also starting a Covid-19 human infection study. The Oxford team will be looking to investigate the immunity provided by previous Covid-19 infections, to learn more about the disease and how we can treat and prevent it.
Human infection studies, also known as human challenge trials, are studies that involve deliberately infecting volunteers with a pathogen in a safe and controlled environment to learn more about the disease or to test potential vaccines or treatments. We believe human infection studies have massive potential to help to tackle Covid-19, from enabling us to better understand the virus, to speeding up vaccine and treatment development. Wellcome has long championed and supported human infection studies and we are thrilled to work with the teams at Oxford, hVIVO and Boyd to utilise them for Covid-19.
Wellcome has committed over £4.8m to support the Oxford study, the first of our investments in Covid-19 human infection studies. We are also working with Boyd who are undertaking discussions with regulators and researchers working on Covid-19 human infection studies, including those at Imperial and Oxford, to understand the regulatory barriers to setting up human infection studies and how evidence and data from these studies could be used more effectively to inform vaccine development. We have also supported the development of the WHO ethics framework for Covid-19 human infection studies and a feasibility report (which essentially is a roadmap of considerations). All of this has been to ensure these studies are done as safely as possible
With so much potential it is brilliant to see the UK being a leader in utilising human infection studies to help end the pandemic. Alongside the Oxford study, the Vaccine Task Force in partnership with Imperial College and hVIVO are using human infection studies to aid their development of Covid-19 vaccines. Outside of the UK, the US government and researchers at the University of Leiden are preparing for Covid-19 human infection studies as well.